Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Earnings for Pacira BioSciences, Inc. (PCRX)
Earnings in 2023 (TTM): $61.7 M
According to Pacira BioSciences, Inc.'s latest financial reports the company's current earnings (TTM) are $61.7 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Pacira BioSciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $61.7 M | $41.96 M |
| 2022 | $13.3 M | $15.91 M |
| 2021 | $56.4 M | $41.98 M |
| 2020 | $20.09 M | $145.52 M |
| 2019 | $-10,748,000 | $-11,016,000 |
| 2018 | $-425,000 | $-471,000 |
| 2017 | $-42,471,000 | $-42,611,000 |
| 2016 | $-37,844,000 | $-37,949,000 |
| 2015 | $2.12 M | $1.86 M |
| 2014 | $-13,543,000 | $-13,716,000 |
| 2013 | $-64,351,000 | $-63,909,000 |
| 2012 | $-52,281,000 | $-52,281,000 |
| 2011 | $-43,328,000 | $-43,328,000 |
| 2010 | $-27,149,000 | $-27,149,000 |
| 2009 | $-28,181,000 | $-31,707,000 |
| 2008 | $-45,587,000 | $-41,862,000 |